Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
05 Aug 2020
Historique:
received: 08 05 2020
accepted: 24 07 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 16 6 2021
Statut: epublish

Résumé

TAK-831 is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO) currently under clinical development for schizophrenia. In this study, a mechanistic multilayer quantitative model that parsimoniously connects pharmacokinetics (PK), target occupancy (TO) and D-serine concentrations as a pharmacodynamic (PD) readout was established in mice. PK, TO and PD time-profiles were obtained in mice and analyzed by mechanistic binding kinetics model connected with an indirect response model in a step wise fashion. Brain distribution was investigated to elucidate a possible mechanism driving the hysteresis between PK and TO. The observed nonlinear PK/TO/PD relationship was well captured by mechanistic modeling framework within a wide dose range of TAK-831 in mice. Remarkably different brain distribution was observed between target and reference regions, suggesting that the target-mediated slow binding kinetics rather than slow penetration through the blood brain barrier caused the observed distinct kinetics between PK and TO. A quantitative mechanistic model for concentration- and time-dependent nonlinear PK/TO/PD relationship was established for TAK-831 in mice with accounting for possible rate-determining process. The established mechanistic modeling framework will provide a quantitative means for multilayer biomarker-assisted clinical development in multiple central nervous system indications.

Identifiants

pubmed: 32901384
doi: 10.1007/s11095-020-02893-x
pii: 10.1007/s11095-020-02893-x
pmc: PMC7478952
doi:

Substances chimiques

D-Amino-Acid Oxidase EC 1.4.3.3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

164

Références

Drug Metab Dispos. 2012 Nov;40(11):2067-73
pubmed: 22837388
J Chromatogr. 1992 Nov 6;582(1-2):41-8
pubmed: 1491056
Drug Discov Today. 2017 Oct;22(10):1447-1459
pubmed: 28476536
Brain Res. 1994 Aug 1;652(2):297-303
pubmed: 7953743
J Neurochem. 2011 Apr;117(2):333-45
pubmed: 21291474
J Pharm Sci. 2013 Sep;102(9):3343-55
pubmed: 23650139
Neurochem Res. 2017 Nov;42(11):3279-3288
pubmed: 28780732
Neuropharmacology. 2011 Oct-Nov;61(5-6):1001-15
pubmed: 21763704
J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):119-25
pubmed: 11419736
Front Mol Biosci. 2018 Jun 12;5:55
pubmed: 29946548
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
pubmed: 17519979
Neurosci Lett. 2020 May 1;726:133664
pubmed: 29966749
AAPS J. 2015 Mar;17(2):462-73
pubmed: 25630504
Schizophr Res. 2010 Aug;121(1-3):125-30
pubmed: 20541910
J Cereb Blood Flow Metab. 2011 Mar;31(3):944-52
pubmed: 20940733
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):777-791
pubmed: 31535440
Drug Metab Dispos. 2009 Jul;37(7):1548-56
pubmed: 19389861
Br J Clin Pharmacol. 2005 Jun;59(6):705-11
pubmed: 15948935
Br J Pharmacol. 2010 May;160(2):389-98
pubmed: 20423348
Br J Pharmacol. 2014 Mar;171(5):1241-9
pubmed: 24670146
J Pharm Sci. 2011 Sep;100(9):3939-50
pubmed: 21254069
Biochem Soc Trans. 2013 Dec;41(6):1551-6
pubmed: 24256253
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):5-20
pubmed: 31674729
J Pharm Sci. 2018 Aug;107(8):2225-2235
pubmed: 29608887
J Cereb Blood Flow Metab. 2013 May;33(5):700-7
pubmed: 23385202
Nat Neurosci. 2011 May;14(5):603-11
pubmed: 21460832
PLoS One. 2011;6(5):e20472
pubmed: 21629771
Pharm Res. 2008 Aug;25(8):1737-50
pubmed: 18058202

Auteurs

Tomoki Yoneyama (T)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan. tomoki.yoneyama@takeda.com.

Sho Sato (S)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Andy Sykes (A)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Cambridge Ltd, Cambridge, UK.

Rosa Fradley (R)

Pharmacology, Takeda Cambridge Ltd, Cambridge, UK.

Stuart Stafford (S)

Pharmacology, Takeda Cambridge Ltd, Cambridge, UK.

Shyam Bechar (S)

Pharmacology, Takeda Cambridge Ltd, Cambridge, UK.

Eimear Howley (E)

Pharmacology, Takeda Cambridge Ltd, Cambridge, UK.

Toshal Patel (T)

Pharmacology, Takeda Cambridge Ltd, Cambridge, UK.

Yoshihiko Tagawa (Y)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Toshiya Moriwaki (T)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Satoru Asahi (S)

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH